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CD46 Is a Cellular Receptor
for Human Herpesvirus 6
(Yamanishi et al., 1988), a usually benign febrile disease
of infancy, that may be accompanied by neurological
complications associated with direct viral invasion of
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Several lines of experimental and clinical evidence
suggest that HHV-6 may act as a cofactor in the courseSummary
of human immunodeficiency virus (HIV) infection, accel-
erating the progression toward full-blown AIDS. MultipleHuman herpesvirus 6 (HHV-6) is the etiologic agent of
positive interactions between HHV-6 and HIV-1 haveexanthema subitum, causes opportunistic infections
been documented (Lusso, 1996): like HIV, HHV-6 prefer-in immunocompromised patients, and has been impli-
entially replicates in CD41 T lymphocytes in vitro, andcated in multiple sclerosis and in the progression of
these cells can be productively coinfected resulting inAIDS. Here, we show that the two major HHV-6 sub-
a dramatic acceleration of cytopathic effects; HHV-6 Agroups (A and B) use human CD46 as a cellular recep-
induces CD4 transcription in cytotoxic effector cells thattor. Downregulation of surface CD46 was documented
are otherwise CD4 negative (i.e., CD81 T cells, NK cells,during the course of HHV-6 infection. Both acute infec-
and gd T cells), rendering them susceptible to HIV infec-tion and cell fusion mediated by HHV-6 were specifi-
tion; moreover, experimental HHV-6 A coinfection in ma-cally inhibited by a monoclonal antibody to CD46; fu-
caques was found to accelerate the progression of sim-sion was also blocked by soluble CD46. Nonhuman
ian immunodeficiency virus infection toward full-blown
cells that were resistant to HHV-6 fusion and entry
AIDS (P. L. et al., unpublished data). Also, several clinical
became susceptible upon expression of recombinant
observations suggest a possible involvement of HHV-6
human CD46. The use of a ubiquitous immunoregulatory in AIDS, including the demonstration of an active and
receptor opens novel perspectives for understanding widespread HHV-6 infection in terminal AIDS patients
the tropism and pathogenicity of HHV-6. (Corbellino et al., 1993; Knox and Carrigan, 1994; Emery
et al., 1999) and the recent correlation between early
acquisition of HHV-6 in infants and rapid progressionIntroduction
of HIV-1 disease (Kositanont et al., 1999). Beyond its
interactions with HIV, HHV-6 may have direct immuno-
Human herpesvirus 6 (HHV-6) is a member of the b-her- suppressive effects in vivo, as suggested by the report
petovirinae subfamily (reviewed in Lusso, 1996; Braun of an HIV-negative child with progressive immunodefi-
et al., 1997; Campadelli-Fiume et al., 1999), first isolated ciency associated with disseminated HHV-6 A and B
from the peripheral blood of immunocompromised pa- coinfection (Knox et al., 1995b). In addition, both HHV-6
tients with lymphoproliferative disorders (Salahuddin et subgroups were recently shown to induce severe thy-
al., 1986). Two major viral subgroups have been defined mocyte depletion in heterochimeric SCID mice en-
(designated A and B) with distinctive genetic, immuno- grafted with human fetal thymic tissue, with a distinctive
logic, and biological traits (Ablashi et al., 1991; Aubin et tropism and cytopathicity for immature thymic precursor
al., 1991; Schirmer et al., 1991). Infection with HHV-6 B cells (Gobbi et al., 1999).
(Lopez et al., 1988) is virtually ubiquitous in the adult No information has been reported regarding the iden-
human population, as it is commonly acquired within tity of the HHV-6 receptor(s). Although HHV-6 A and B
the first two years of life and persists for the entire preferentially replicate in CD41 T lymphocytes, both viral
lifetime. At present, little is known about the epidemio- subgroups were shown to infect a broader range of
logical distribution of HHV-6 A. Primary HHV-6 B infec- cells of different lineage origin, either productively or
tion has been etiologically linked to exanthema subitum nonproductively (Lusso, 1996; Braun et al., 1997; Cam-
padelli-Fiume et al., 1999); these results suggest that
the viral receptor(s) must be widely expressed. Evidence§ To whom correspondence should be addressed (e-mail: paolo.
lusso@hsr.it). has been provided against the involvement of the CD4
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glycoprotein (Lusso et al., 1989), which is a critical re- shown). Figure 1 shows that CD46 was progressively
downmodulated beginning at day 4, and was virtuallyceptor for both HIV (Sattentau and Weiss, 1988) and
HHV-7 (Lusso et al., 1994). In contrast with the broad lost from the cell surface by day 6. By contrast, none
of the other target cell antigens was significantly af-tropism for different human cell types, the species host-
range of HHV-6 is narrow, with only a restricted number fected by HHV-6 infection. Results are shown in Figure
1 for CD4, as well as for two widely expressed leukocyteof nonhuman primate species showing susceptibility in
vitro and/or in vivo (Lusso, 1996; Braun et al., 1997; surface markers, CD43 and CD44 (Figure 1). Thus, the
dramatic CD46 downmodulation was not simply a reflec-Campadelli-Fiume et al., 1999). Although postviral entry
restriction factors might contribute to the observed spe- tion of a nonspecific abatement of the cellular protein
synthesis or other cytopathic effects commonly inducedcies restriction of HHV-6, the above studies suggest that
the viral receptor(s), or at least one critical component by herpesvirus infections. Progressive loss of surface
CD46 expression was also documented in CD41 T lym-thereof, has a marked degree of species specificity.
In this report, we present diverse lines of evidence phocytes infected with HHV-6 strain Z29 (subgroup B),
although the time course of gH expression and CD46indicating that human CD46 is a cellular receptor for
both major subgroups of HHV-6. CD46, also designated downregulation was consistently slower than observed
with strain GS (data not shown). The finding that CD46membrane cofactor protein, is a ubiquitous type-I glyco-
protein expressed on the surface of all nucleated human is selectively downmodulated during the course of HHV-6
infection represents a first criterion for defining a spe-cells examined to date (reviewed in Liszewski et al.,
1991; Seya, 1995). It is a member of a family of glycopro- cific viral receptor.
teins acting as regulators of complement activation
(RCA), which function to prevent spontaneous activation Specific Inhibition of HHV-6 Infection by
of complement on autologous cells. CD46 has been an Anti-CD46 Monoclonal Antibody
identified as a primate-specific cellular receptor for vac- To investigate whether CD46 is required for HHV-6 infec-
cine strains of measles virus (MV) (DoÈ rig et al., 1993; tion, we examined the effects of a murine anti-CD46
Naniche et al., 1993), with multiple isoforms displaying monoclonal antibody (mAb) (J4.48) on acute HHV-6 in-
receptor function (Manchester et al., 1994); however, fection. Strains belonging to both subgroup A (GS) and
the relevance of CD46 for the entry of wild-type MV subgroup B (Z29) were tested, using activated periph-
isolates remains controversial (Buckland and Wild, 1997; eral blood mononuclear cells (PBMC) as targets; viral
Sakata et al., 1998). CD46 has also been implicated as replication was assessed by measuring the accumula-
a keratinocyte attachment receptor for group A Strepto- tion of viral genomes using a real-time quantitative cali-
coccus (Okada et al., 1995), and as an epithelial pilus brated PCR assay. Figure 2 demonstrates that the
receptor for pathogenic Neisseria (Kallstrom et al., anti-CD46 mAb markedly inhibited infection with both
1997). Also of note is the fact that other members of HHV-6 isolates, as shown by blockade of accumulation
the RCA family serve as viral receptors, i.e., CD21 for of cell-associated virus; similarly, both the accumulation
Epstein-Barr virus (Yefenol et al., 1976; Fingeroth et al., of extracellular HHV-6 genome equivalents and the ex-
1984) and CD55 for several echoviruses (Bergelson et pression of an early-late nuclear HHV-6 antigen (p41)
al., 1994) and coxsackieviruses (Bergelson et al., 1995). were inhibited (data not shown). By contrast, a control
These findings suggest the existence of common biolog- mAb (anti-CD44) had minimal effects. Moreover, the
ical or structural features that favor the exploitation of anti-CD46 mAb displayed no inhibitory activity against
this class of molecules by infectious agents. Our demon- HIV-1 infection of PBMC (data not shown). These results
stration that CD46 serves as a receptor for HHV-6 opens suggest that the CD46 glycoprotein plays an essential
novel perspectives on the biology of this emerging hu- role in the infectious cycle of HHV-6.
man pathogen.
Specific Inhibition of HHV-6-Mediated Membrane
Fusion by an Anti-CD46 mAbResults
and by Soluble CD46
To test whether CD46 is required for the early membraneSelective Downregulation of Membrane CD46
Expression during the Course fusion events associated with HHV-6 entry into target
cells, we employed a variation of a vaccinia-based cellof HHV-6 Infection
As an initial approach to identify a surface receptor for fusion assay that was originally developed to quantitate
the functional interactions of the HIV-1 envelope glyco-HHV-6, we examined a large panel (.30) of cell surface
antigens for selective downregulation during the course proteins with CD4 (Nussbaum et al., 1994) and later
enabled the identification and characterization of fusin/of in vitro infection; all the antigens tested are expressed
on human T cells, which represent a primary target for CXCR4 as the first HIV-1 coreceptor (Feng et al., 1996).
The system has also been used to characterize fusionboth viral subgroups (A and B). In vitro±activated primary
human CD41 T lymphocytes were infected with HHV-6 mediated by MV glycoproteins and CD46 (Nussbaum et
al., 1995). In these systems, fusion is measured betweenA (strain GS); a high multiplicity of infection (MOI) was
employed in order to initiate uniform infection in the effector cells expressing vaccinia-encoded recombi-
nant viral glycoproteins and target cells expressing thetarget cell population. Longitudinal fluorocytometric
analysis revealed a progressive expression of gH, a viral appropriate receptor(s); quantitation is achieved by a
vaccinia-based reporter gene readout that measuresenvelope glycoprotein, between days 4 and 6 postinfec-
tion (Figure 1); this effect paralleled the appearance of fusion-dependent activation of the E. coli LacZ gene
by the bacteriophage T7 RNA polymerase. We havetypical HHV-6-induced cytomorphological changes (not
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Figure 1. Progressive Downmodulation of Surface CD46 during HHV-6 Infection
Primary human CD41 T lymphocytes, enriched from adult peripheral blood, were activated with PHA and then infected with HHV-6 A (strain
GS) at the MOI of 5. Analysis of surface membrane expression of CD4, CD43, CD44, CD46, and HHV-6 glycoprotein H was conducted at the
indicated time points by indirect immunofluorescence followed by fluorocytometry (solid profiles); background fluorescence levels were
revealed with an irrelevant mAb (empty profiles). Uninfected homologous cells are presented as a control.
adapted this technology to study fusion mediated We used this system to test whether CD46 is required
for HHV-6-mediated cell fusion. As illustrated in Figureby HHV-6 (P. L. et al., unpublished data), for which
the critical glycoproteins remain unidentified. In this 3A, HHV-6 A (strain GS)-infected PBMC showed fusion
activity with HeLa target cells; the mAb directed againstmethod, effector cells are generated by infecting a per-
missive cell type with cell-free HHV-6 at high MOI; the HHV-6 glycoprotein H, which has been implicated in
virus infectivity/syncytia formation (Campadelli-Fiumeeffectors are then tested for fusion with permissive tar-
get cells, using the vaccinia-based reporter gene read- et al., 1999), caused a dose-dependent inhibition,
thereby verifying the specificity of the observed fusion.out. We have found that several human cell lines and
primary cell types are competent for HHV-6-mediated Figure 3A shows that the anti-CD46 mAb J4.48 potently
blocked HHV-6 A-mediated fusion in a dose-dependentfusion, with the human cervical carcinoma cell line HeLa
showing a particularly robust activity (P. L. et al., unpub- fashion; by contrast, mAbs directed against other sur-
face molecules (i.e., CD2, CD4, CD44) had no effects.lished data).
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Figure 3. Specific Inhibition of HHV-6 A±Mediated Cell Fusion by
Figure 2. A Murine Anti-CD46 mAb Specifically Blocks Productive
an Anti-CD46 mAb and by Soluble CD46
HHV-6 Infection
(A) Effect of mAbs directed against cellular antigens or glycoprotein
Time course of accumulation of cell-associated virus in the course
H of HHV-6. Target cells were pretreated for 30 min at room tempera-
of infection by HHV-6 A (strain GS; panel A) or B (strain Z29; panel
ture with mAbs against CD2, CD4, CD44, or CD46; alternatively,
B). Human PBMC were activated in vitro with PHA, treated for 30
effector cells were preincubated with the anti-HHV-6 gH mAb. The
min with mAbs to human CD44 or CD46 (used at 50 mg/ml) and then
mAbs were maintained at the indicated concentrations throughout
exposed to HHV-6 at the MOI of 0.1. After 2 hr at 378C, the cells
the fusion assay.
were washed extensively and recultured in the presence of the mAbs
(B) Effect of soluble CD46 and soluble CD4 proteins. Effector cells
at the original concentration. Total DNA was extracted from 105 cells
were pretreated for 30 min at room temperature with the indicated
collected at the indicated time points, and the number of HHV-6
volumes of culture supernatants of cells infected with vaccinia re-
genome equivalents was measured by quantitative calibrated real-
combinants encoding either sCD46 or sCD4, concentrated 80-fold
time PCR. Data are expressed as number of HHV-6 genome equiva-
by Centricon 30 ultrafiltration; as additional controls, effector cells
lents per cell; each data point represents the mean of duplicate
were pretreated with the corresponding low molecular weight fil-
samples with error bars denoting the SEM. Results are representa-
trates, depleted of the recombinant proteins, which were in turn
tive of several experiments with similar outcome.
concentrated 80-fold using Centricon 3. The soluble proteins were
maintained at the same levels throughout the fusion assay.
Fusion was quantitated between HHV-6 A (strain GS)±infected hu-
man PBMC effectors expressing vaccinia-encoded T7 polymeraseSimilar data (not shown) were obtained with other target
and HeLa cell targets infected with a vaccinia recombinant encodingcell types of different lineage origin. Moreover, both the
the LacZ gene linked to the T7 promoter. The data are expressedanti-CD46 and the anti-gH mAbs, but not control mAbs,
as percent of the control b-galactosidase values obtained in the
blocked membrane fusion induced by HHV-6 B (strain absence of inhibitors, after subtracting the low background values
Z29) (data not shown). (consistently below 2 OD units per minute) obtained with both ef-
As an additional test of the role of CD46 in HHV-6- fector and target cells cultured alone. Each data point denotes the
mean of duplicate samples, with error bars indicating the SEM.mediated membrane fusion, we examined the effects of
Results are representative of several experiments with similara soluble recombinant protein representing the human
outcome.CD46 ectodomain (sCD46), produced in mammalian
cells using recombinant vaccinia technology; the soluble
ectodomain of human CD4 (sCD4), produced in a similar
viruses: HHV-6, HIV-1, and MV. Effector cells includedfashion, was tested in parallel as a negative control. The
NIH 3T3 murine fibroblasts expressing either vaccinia-culture supernatants containing each secreted protein
encoded HIV-1 envelope glycoproteins (LAV isolate,were concentrated 80-fold by Centricon ultrafiltration;
CXCR4-specific) or vaccinia-encoded MV (Edmonstonthe low molecular weight (,30 kDa) flow-through fil-
strain) hemagglutinin (H) plus fusion (F) glycoproteins,trates were in turn concentrated 80-fold and used as
and primary human PBMC productively infected withadditional negative controls. As illustrated in Figure 3B,
HHV-6 A (strain GS). A HeLa transfectant cell line stablysCD46 inhibited HHV-6-mediated fusion in a dose-
expressing human CD4 (HeLa-CD4) was used as a com-dependent manner; by contrast, neither sCD4 nor the
mon target, since it is fusion permissive for all threelow molecular weight filtrates showed any effects.
viruses. As shown in Table 1, both the anti-CD46 mAbTo further verify the specificity of the observed effects,
J4.48 and sCD46 efficiently blocked HHV-6-mediateddifferent blockers of specific virus-receptor interactions
were tested against fusion mediated by three distinct and MV glycoprotein-mediated fusion, while having no
CD46 as an HHV-6 Receptor
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RK13. Fluorocytometric analysis using mAb J4.48 con-Table 1. Specific Inhibition of Cell Fusion Induced by HHV-6,
firmed CD46 expression on .98% of the transfectedMV, and HIV-1 Glycoproteins
cells, with a mean fluorescence intensity of 500 com-
Percent Inhibition of Cell Fusion
pared to 5 for the untransfected parental cells (data notMediated by:
shown). As illustrated in Figure 4C, the CD46 transfec-
Inhibitor HHV-6 MV HIV-1 tant was competent for HHV-6-mediated fusion, which
was specifically blocked by both anti-CD46 and anti-gHAnti-CD46 88.4 97.8 8.8
Soluble CD46 81.1 65.0 0.0 mAbs; by contrast, only a low background activity was
Anti-CD4 0.0 6.3 98.3 seen with untransfected parental cells.
Soluble CD4 6.7 0.0 65.9
Anti-CD43 0.0 0.0 0.0
Expression of Recombinant Human CD46 Renders
The effector cells were primary human PBMC infected with HHV-6 Nonhuman Cells Permissive for HHV-6 Entry
A (strain GS) or murine NIH 3T3 cells infected with vaccinia recombi- To extend our analysis of the early events of HHV-6
nants encoding either the MV glycoproteins H and F or the HIV-1
infectivity, we employed a viral entry assay, based onenvelope glycoproteins. HeLa-CD4 cells were employed as common
HHV-6 DNA quantitation by calibrated real-time PCR, infusion targets. To test the inhibitory effect of mAbs or soluble pro-
which trypsin resistance was interpreted as a measureteins, target cells were pretreated with the indicated mAbs (each at
40 mg/ml) and effector cells with concentrated culture supernatants of virus entry into the target cells. The mouse T cell line
containing the indicated soluble proteins (each at 40 ml/200 ml). Data EL-4 was infected either with the vaccinia recombinant
represent the mean of duplicate samples and are expressed as encoding human CD46, or with a control vaccinia virus.
percent inhibition of the b-galactosidase values measured in the
Each group of target cells was incubated at 378C withcontrol untreated cultures, after subtracting the low background
cell-free HHV-6 A (strain GS) or HHV-6 B (primary strainvalues (consistently below 4% of the activity seen with fusion-per-
PL1) for 2 or 6 hr, respectively, and then extensivelymissive cells) measured in both effectors and targets cultured alone.
washed. Separate aliquots of cells were either pro-
cessed directly, or subjected to trypsin treatment and
then processed; total cellular DNA was extracted fromsignificant effect on HIV-1 glycoprotein-mediated fu-
each sample for PCR quantitation of HHV-6 genomesion. By contrast, both the anti-CD4 mAb BL-4 and sCD4
equivalents. As shown in Figure 5, expression of humaneffectively blocked HIV-1 glycoprotein-mediated fusion,
CD46 greatly enhanced HHV-6 penetration into the cells.but were ineffective against fusion mediated by HHV-6
Thus, the absolute amount of trypsin-resistant virus wasor MV glycoproteins.
elevated 25-fold for subgroup A and 11-fold for sub-Taken together, the loss-of-function results obtained
group B; in both cases, the major fraction of the cell-with an anti-CD46 mAb indicate that CD46 is necessary
associated virus was rendered trypsin-resistant byfor both HHV-6 infectivity and HHV-6-mediated mem-
CD46 expression. Similar results (not shown) were ob-brane fusion. Moreover, the fusion activity is selectively
tained with a stable CD46 transfectant of EL-4, com-blocked by a soluble form of the CD46 glycoprotein.
pared to the CD46-negative parental cell line. To assessThus, CD46 meets two additional criteria for an essential
whether HHV-6 infection in nonhuman cells could pro-HHV-6 receptor.
ceed beyond the viral entry step, the expression of an
early-late nuclear HHV-6 antigen (p41) was measured inExpression of Recombinant Human CD46 Renders
a stable CD46 transfectant of EL-4 at various time pointsNonhuman Cells Permissive for HHV-6-Mediated
after exposure to the virus. No p41 was detected overMembrane Fusion
the 10-day period after exposure to the virus, suggestingThe vaccinia-based cell fusion system can be used to
that additional restriction factors acting beyond the viralassess whether recombinant expression of a putative
entry step limit the replication of HHV-6 in nonhumanviral receptor renders a target cell permissive for fusion
cells.(Nussbaum et al., 1994, 1995; Feng et al., 1996). In a
Taken together, the gain-of-function experiments de-separate study, we have found that cell lines derived
scribed in the previous two sections indicate that ex-from diverse nonhuman species, including mice, chi-
pression of recombinant CD46 confers HHV-6 fusionnese hamsters, rabbits and baboons, are incompetent
and infection susceptibility to otherwise resistant non-for fusion with HHV-6-infected cells (P. L. et al., unpub-
human target cells. Thus, CD46 meets a fourth criticallished data). We tested the ability of vaccinia-encoded
criterion for a specific HHV-6 receptor.full-length human CD46 to confer HHV-6 fusion permis-
siveness to mouse NIH 3T3 fibroblasts. Figure 4A docu-
ments the surface expression of recombinant CD46 us- Human CD46 Is Not Sufficient for HHV-6 Fusion
and Infectivitying fluorocytometry with mAb J4.48; cells infected with
a control vaccinia virus gave only a background signal. We screened a panel of human CD41 T cell lines for
susceptibility to fusion and infection by HHV-6 A (strainAs shown in Figure 4B, vaccinia-encoded human CD46
rendered NIH 3T3 cells competent for fusion induced GS). As summarized in Table 2, all the cell lines ex-
pressed significant levels of CD46; however, whereasby both HHV-6 A (strain GS) and HHV-6 B (primary strain
PL1). The fusion activity was strongly inhibited by mAbs several were found to be permissive targets for HHV-6 in
both fusion and infectivity assays, others proved non-directed against CD46 or HHV-6 gH, but minimally by
the control anti-CD44 mAb. Similar data (not shown) permissive in both assays. We evaluated the possibility
that the CD46 glycoprotein endogenously expressed onwere obtained with other nonhuman cell types. Permis-
siveness for HHV-6-mediated fusion was also tested in these nonpermissive cell lines might be functionally in-
competent as an HHV-6 receptor (e.g., due to an inactivea stable CD46 transfectant of the rabbit kidney cell line
Cell
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CD46 isoform, or to genetic alterations related to the
neoplastic origin of the cells). Thus, PM1 cells were
infected with the vaccinia recombinant encoding CD46
(shown above to function as an HHV-6 receptor in both
fusion and entry assays); still, the cells remained refrac-
tory to HHV-6-mediated fusion, despite markedly in-
creased surface CD46 expression (Table 2). As an addi-
tional control, wild-type PM1 cells were found to be
permissive for fusion mediated by MV glycoproteins
(data not shown), indicating that the native CD46 on
these cells can function as an MV receptor. These results
suggest the existence of an additional cellular factor,
possibly a viral coreceptor, that is critical for HHV-6
fusion and infection.
Discussion
We demonstrate herein that human CD46 is an essential
cellular receptor for HHV-6. This conclusion is based on
several complementary lines of evidence which, to-
gether, have represented essential criteria for identifying
the receptors of other enveloped viruses (e.g., CD4 [Sat-
tentau and Weiss, 1988] and chemokine receptors [Ber-
ger et al., 1999] for HIV; CD46 for MV [DoÈ rig et al., 1994];
and herpes virus entry mediator A [HveA] for herpes
simplex virus 1 [HSV-1; Montgomery et al., 1996]). First,
CD46 was selectively and progressively downregulated
from the target cell surface during the course of HHV-6
infection. Second, in analyses of HHV-6 infectivity and
HHV-6-mediated cell fusion, evidence of loss-of-func-
tion was obtained using a CD46-specific mAb. Third, a
soluble form of CD46 was able to block HHV-6-mediated
cell fusion. Fourth, gain-of-function studies demon-
strated that expression of recombinant human CD46
rendered nonhuman cells susceptible to both HHV-6-
mediated fusion and HHV-6 entry. Furthermore, our re-
sults document CD46 usage not only by laboratory-
adapted HHV-6 strains, but also by a primary isolate
(PL1, subgroup B) that had been passaged only once
in primary human cells. It is critical that parallel results
were obtained using virus infectivity/entry assays, which
assess biological properties of intact HHV-6 virions, and
cell fusion assays, which measure functional activities
of the corresponding HHV-6 fusion components (pre-
sumably viral envelope glycoproteins expressed on the
Figure 4. Expression of Recombinant Human CD46 Renders Non- cell surface).
human Cells Permissive for HHV-6-Mediated Cell Fusion An important direction for future work will be to iden-
(A) Fluorocytometric analysis of recombinant CD46 surface expres- tify the putative HHV-6 glycoprotein(s) that physically
sion. Murine NIH 3T3 fibroblasts were infected with a vaccinia re-
interacts with CD46. The analogous question has beencombinant (vCB-48) encoding full-length human CD46; homologous
addressed for HSV-1 with the identification of the viralcells infected with an irrelevant vaccinia recombinant (vTF-7.3)
glycoprotein D as the HveA-binding component (Whit-served as a negative control. Staining was performed using the anti-
CD46 mAb J4.48 (solid profiles) or, as a negative control, with an beck et al., 1997). Moreover, as documented for some
irrelevant mAb (empty profiles). other enveloped viruses, additional HHV-6 glycopro-
(B) Effect of recombinant human CD46 expression on HHV-6-medi- tein(s), not directly involved in binding the receptor, are
ated cell fusion. The target cells were NIH 3T3 cells either infected
with a vaccinia recombinant encoding LacZ (2CD46) or coinfected
with the latter and the vaccinia recombinant encoding human CD46
(1CD46). Fusion was measured with the indicated effector cells: For additional specificity determinations, the indicated mAbs were
PBMC infected with HHV-6 A (strain GS) or SupT1 cells infected used: anti-HHV-6 gH (at 10 mg/ml) against effector cells; anti-CD46
with HHV-6 B (primary isolate PL1). or anti-CD44 (each at 50 mg/ml) against target cells. The mAbs were
(C) Effect of stable expression of human CD46 on HHV-6-mediated preincubated with either the effector or the target cells and then
cell fusion. The target cells were RK13 rabbit kidney cells stably maintained at the original concentration throughout the fusion
transfected with human CD46. Homologous untransfected cells assay. The data shown denote the mean of duplicate samples, with
were used as a control. Effector cells were human PBMC infected error bars indicating the SEM. Results are representative of several
with HHV-6 A (strain GS). experiments with similar outcome.
CD46 as an HHV-6 Receptor
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Table 2. Susceptibility of Human CD41 T Cell Lines to Fusion




Cell Line CD4 CD46 Fusionb Replicationc
SupT1 111 11 11 111
Jurkat 1 11 11 11
Molt-3 11 11 1 1
12D7 111 11 1/2 1
CEMx174 111 11 2 2
Hut78 11 11 2 2
H9 11 11 2 2
PM1 11 11 2 2
PM1-vCD46d 11 1111 2 NT
a Antigen expression, assessed by fluorocytometry, was graded as
follows: 2, no signal over background fluorescence; 1, mean fluo-
rescence intensity between 100 and 101; 11, between 101 and 102;
111, between 102 and 103; 1111, greater than 103.
b Cell fusion was graded as follows: 2, b-galactosidase activity lower
or equal to values obtained with uninfected effector cells used as
a negative control; 1/2, less than 3 times higher than the negative
control; 1, between 3 and 10 times higher; 11, more than 10 times
higher.
c Virus replication was graded as follows: 2, no expression of HHV-6
Figure 5. Recombinant Human CD46 Renders Nonhuman Cells Per-
gH; 1, less than 10% of the cells expressing gH at any time between
missive for HHV-6 Entry
day 3 and day 10 postinfection; 11, 10%±50% positive; 111,
Murine T lymphoblasts (EL-4) were infected with a vaccinia recombi- progressive infection with widespread gH expression and massive
nant encoding full-length human CD46 or with a control vaccinia. cytopathic effect by day 7 postinfection. NT, not tested.
Analysis by fluorocytometry confirmed CD46 expression on .90% d Infected with a vaccinia recombinant encoding full-length human
of the cells infected with the CD46-encoding vaccinia. The cells CD46.
were subsequently washed and exposed to cell-free HHV-6 at the
MOI of 5. After incubation at 378C for 2 hr (strain GS; panel A) or 6
hr (strain PL1; panel B), the cells were harvested and extensively
washed. One aliquot was processed directly (empty bars); a second factor besides CD46, possibly a viral coreceptor, that
aliquot was subjected to trypsin treatment for 10 min at 378C and is not uniformly present in all human cell types. The
then processed (solid bars). Total cellular DNA was extracted, and requirement for multiple distinct receptors is well docu-
HHV-6 DNA was determined by quantitative calibrated real-time
mented for other enveloped viruses such as HIV-1 (Ber-PCR; the GAPDH gene was used as an internal standard to normalize
ger et al., 1999) and HSV-1 (Tufaro, 1997). However, ourfor cell number. Trypsin resistance was interpreted as a measure
results do not formally exclude the possibility that theof viral entry. Each data point represents the mean of triplicate
samples, with error bars indicating the SEM. The results are repre- fusion-negative phenotype of certain CD46-positive hu-
sentative of several experiments with similar outcome. man cells reflects the presence of a hypothetical in-
hibitory factor; such a factor would have to act selec-
tively against HHV-6 since the endogenous CD46
expressed on PM1 cells (nonpermissive for HHV-6) waslikely to be required for the fusion reaction. Extension
of our fusion system through the use of recombinant found to be functional for MV-mediated fusion. A sec-
ond-level restriction of HHV-6 replication in some humanHHV-6 proteins will facilitate new experimental direc-
tions, including identification of putative coreceptor(s), cells, that cannot be explained by CD46, is manifested
downstream of the viral entry step. Nonproductive infec-analysis of the molecular mechanism by which receptor
interactions lead to virus fusion/entry, and characteriza- tion has been documented in several human cells and
tissues (Lusso, 1996; Braun et al., 1997; Campadelli-tion of antibodies or other inhibitors that block HHV-6
at the fusion/entry level. Fiume et al., 1999), including both primary and immortal-
ized epithelial cells such as HeLa cells (Chen et al.,The discovery that HHV-6 exploits a virtually ubiqui-
tous human molecule as a surface receptor may help 1994) which we found to be highly permissive for HHV-
6-mediated fusion (P. L. et al., unpublished data). Ato explain the broad cellular tropism of this virus, and
thereby opens new perspectives on the diverse clinical related complexity that emerges from the present study
is that both HHV-6 subgroups (A and B) exploit CD46manifestations to which HHV-6 has been linked. Never-
theless, not all aspects of the HHV-6 cytotropism can for fusion/entry, yet these viruses display differing tro-
pisms for infection of certain T cell lines. Restrictionsbe explained by CD46 usage. Indeed, we have shown
that this receptor is not sufficient to enable HHV-6 fu- at the entry stage (e.g., use of different putative corecep-
tors) and/or at subsequent postentry replication stepssion/entry, since some human T cell lines were found
to be nonpermissive for HHV-6-mediated fusion and rep- may contribute to the different biological properties and,
possibly, pathogenic activities of HHV-6 A and B. Thus,lication despite the presence of significant surface CD46
levels; furthermore, high-level expression of recombi- the discovery of the HHV-6 receptor function of CD46
represents only the first molecular window into the com-nant CD46 failed to overcome the fusion restriction in
these cells. The simplest interpretation of these findings plex mechanisms governing the tropism of this virus for
different target cells and tissues.is that HHV-6-mediated fusion requires an additional
Cell
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centrifugation. To enrich for CD41 T lymphocytes, PBMC were la-The absence of a functional CD46 receptor most likely
beled with a cocktail of mAbs to CD8 (Ortho), CD14, CD19, andrepresents a critical determinant of the restricted spe-
CD56 (Becton Dickinson), then washed twice in PBS supplementedcies host-range documented for HHV-6 replication
with 1% FBS and incubated for 30 min at 48C with goat-anti-mouse-
(Lusso, 1996; Braun et al., 1997; Campadelli-Fiume et al., conjugated immunomagnetic beads (Dynal) at a bead-to-cell ratio
1999) and confirmed for HHV-6-mediated fusion (P. L. of 10:1, under continuous rotation. Negative cells were enriched by
two subsequent passages on a magnet. The human T cell lineset al., unpublished data); also, our findings indicate that
SupT1 and Molt-3 were provided by D. V. Ablashi, Advanced Bio-postentry restriction factors may further limit viral ex-
technology Inc., CEMx174 was obtained from the NIH AIDS Re-pression in nonhuman cells. Additional studies are re-
search and Reference Reagent Program, and all the other cell linesquired to assess the HHV-6 receptor activity of CD46
were obtained from the American Type Culture Collection. The mu-
glycoproteins derived from diverse nonhuman species. rine mAbs used for fluorocytometry and blocking experiments were:
In this respect, the mouse model is particularly intrigu- anti-CD2 (Ortho), anti-CD4 (BL-4), CD43, CD44 and CD46 (J4.48) (all
from Coulter-Immunotech), anti-HHV-6 p41 (9A5D12; a gift of Dr.ing, since the failure of mouse cells to support HHV-6
Balachandran, University of Kansas), and anti-HHV-6 gH (gp102;replication and fusion may reflect not only different
Virotech International).properties of the murine CD46 homolog, but also its
testis-restricted expression pattern (Tsujimura et al.,
Viruses and Infection Procedure1998). Transgenic mice expressing human CD46 are
The viral strains used in this study were: HHV-6 A, strain GS (Sala-
likely to be valuable tools for studying the pathologic huddin et al., 1986), HHV-6 B, strain Z29 (Lopez et al., 1988) and
consequences of HHV-6 infection, as they are proving HHV-6 B, isolate PL1 (Lusso, unpublished); the latter is a primary
to be for MV. Of particular interest is the recent descrip- isolate derived from the PBMC of a healthy blood donor and pas-
saged in vitro only once in primary human cord blood CD41 T cells.tion of a transgenic mouse line in which the CD46 ex-
The viral stocks were obtained by growing viruses in primary humanpression pattern closely parallels that found in humans
cord blood CD41 T cells and collecting cell-free culture supernatants(Oldstone et al., 1999).
by high-speed centrifugation and filtration at the time of maximal
The fact that HHV-6 uses a complement regulatory viral antigen expression, as assessed by both fluorocytometry (see
protein as a receptor may have significant implications below) and indirect immunofluorescence on acetone-fixed cells us-
for the viral pathogenetic mechanisms. CD46 plays a ing a mAb against the p41 early-late nuclear antigen, as previously
described (Lusso et al., 1994). The viral stocks were analyzed bycritical physiological role in preventing spontaneous ac-
ultrasensitive nested PCR for potential contamination with the heter-tivation of the complement cascade on the surface of
ologous HHV-6 subgroup or with HHV-7, and found to be consis-autologous cells, which could result in extensive cytoly-
tently negative. For experiments of acute infection, PBMC or CD41 T
sis and widespread tissue damage. Its importance in cells were activated for 48 hr with phytohemagglutinin (PHA; Sigma);
the homeostasis of the organism is underscored by its infection was carried out by incubating the cells for 2 hr at 378C
constitutive expression on all nucleated human cells with cell-free HHV-6 stocks at the indicated MOI. The cells were
subsequently cultured (5 3 105/ml) in RPMI supplemented with 10%tested to date (Liszewski et al., 1991; Seya, 1995). Based
fetal bovine serum (FBS) in the absence of exogenous interleukin 2.on in vitro studies, it has been suggested that perturba-
tion of CD46 may directly underlie some of the patho-
Fluorocytometric Analysislogic manifestations of infection by MV, which also uses
Fluorocytometric analysis was used to determine the levels of differ-
CD46 as a receptor and causes immunosuppression. ent cell surface markers, as well as of HHV-6 glycoprotein H. An
For example, it has been shown that MV engagement irrelevant IgG1 mAb (Sigma) was used to assess background fluores-
of CD46 may lead to increased complement sensitivity cence levels. The cells were washed with cold phosphate buffered
saline (PBS) supplemented with 1% FBS and incubated with the(Schnorr et al., 1995), cytokine dysregulation, including
mAbs for 30 min at 48C. After two washes in PBS, the cells werereduced IL-12 secretion (Karp et al., 1996) and enhanced
incubated for additional 30 min with fluorescein isothiocyanate-IL-6 secretion (Ghali and Schneider-Schaulies, 1998),
conjugated goat-anti-mouse antiserum (Sigma). The cells were
and nitric oxide production (Hirano et al., 1999). Of po- again washed twice in PBS and fixed with 2.5% formaldehyde in
tential interest for the putative involvement of HHV-6 in PBS. Fluorocytometric analysis was performed using a FacScan
the progression of HIV disease, a decreased expression analyzer (Becton Dickinson). Appropriate gating was used to ex-
clude dead cells; at least 10,000 events were accumulated for eachof surface CD46 has been documented in lymphoid cells
sample.from HIV-infected people (Jarvis et al., 1995). Moreover,
CD46 was found to be directly incorporated into the
Quantitation of HHV-6 DNA by Real-Time Quantitative PCRmembrane of HIV virions, possibly contributing to pro-
HHV-6 replication and entry were assessed by quantitative cali-tection of the virus from complement-mediated lysis
brated PCR for HHV-6 DNA, based on the ABI PRISM 7700 TaqMan
(Montefiori et al., 1994); this suggests an opportunity for technology; quantitative detection systems for human b-actin and
direct binding and fusion interactions between HHV-6 rodent GAPDH (both from Perkin-Elmer) were used for cell number
and HIV virions. Another important area of clinical inves- normalization for human and murine cells, respectively. Details
about the PCR amplification and real-time detection technique willtigation is multiple sclerosis, in which downmodulation
be reported elsewhere (G. L. et al., unpublished data). Briefly, totalof CD46 in the affected neural tissue might constitute
DNA was extracted from 105 cells using the phenol-chloroforman immunopathogenetic factor. These concepts provide
method. As negative controls, we used uninfected cells (105/sample)
a starting point for studying the relationship between from the Molt-3 cell line, which were processed in parallel starting
HHV-6 receptor usage, viral tropism, and pathogenesis with the DNA extraction step; one negative control was added after
of HHV-6 infection. each test sample. PCR was performed using an ABI PRISM 7700
Detection System (Perkin-Elmer), starting with 528C for 2 min and
958C for 15 min followed by 40 cycles of amplification (15 s at 958C,Experimental Procedures
1 min at 588C). All the primers were used at 0.3 mM; all the probes
were used at 0.2 mM. The number of viral genome equivalents wasCells and Monoclonal Antibodies
calculated on the basis of the threshold cycle values recorded forPrimary human PBMC were derived from Leukopak preparations
obtained from healthy adult blood donors by gradient (BioWhittaker) duplicate amplification curves obtained from each test sample.
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Cell Fusion Mediated by Viral Glycoproteins volume of 0.3 ml. After incubation at 378C for 2 hr (for HHV-6 A) or
6 hr (for HHV-6 B), the cells were extensively washed and eachA vaccinia-based cell fusion assay was employed, as originally de-
veloped to study the functional interaction of recombinant HIV enve- culture was subdivided in two aliquots: one was incubated for 10
min at 378C with 0.25% trypsin; the other in MEM 2.5 without trypsin.lope glycoproteins with CD4 (Nussbaum et al., 1994), and subse-
quently applied to the interaction of recombinant MV glycoproteins The cells were then washed three times with cold PBS and the dry
cellular pellets were frozen and stored at 2808C. Total cellular DNAwith CD46 (Nussbaum et al., 1995). In these systems, cell fusion is
quantitated based on the selective expression of the E. coli LacZ was extracted by the chloroform-phenol method. The number of
cell-associated HHV-6 genome equivalents was assessed by cali-gene in fused cells. Adaptation of this system to study HHV-6-
mediated fusion will be reported in detail elsewhere (P. L. et al., brated quantitative real-time PCR; a quantitative system for rodent
GAPDH (reactive with mouse GAPDH) was used to normalize forunpublished data). Briefly, effector cells were prepared by infecting
suitable cell types with HHV-6 using an MOI of 5; in vitro±activated cell number. Trypsin resistance was interpreted as a measure of
viral entry.PBMC were employed for HHV-6 A (strain GS) and the SupT1 cell
line for HHV-6 B (strains Z29, PL1). Uninfected homologous cells
were tested in parallel as background controls. Aliquots of the HHV- Acknowledgments
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